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Circulating exosomes suppress the induction of
regulatory T cells via let-7i in multiple sclerosis
Kimitoshi Kimura1,2, Hirohiko Hohjoh3, Masashi Fukuoka3, Wakiro Sato1,4, Shinji Oki1, Chiharu Tomi1,
Hiromi Yamaguchi1, Takayuki Kondo2,5, Ryosuke Takahashi2 & Takashi Yamamura1,4
Multiple sclerosis (MS) is a T cell-mediated autoimmune disease of the central nervous
system. Foxp3+ regulatory T (Treg) cells are reduced in frequency and dysfunctional in
patients with MS, but the underlying mechanisms of this deﬁciency are unclear. Here, we
show that induction of human IFN-γ−IL-17A−Foxp3+CD4+ T cells is inhibited in the presence
of circulating exosomes from patients with MS. The exosomal miRNA proﬁle of patients with
MS differs from that of healthy controls, and let-7i, which is markedly increased in patients
with MS, suppresses induction of Treg cells by targeting insulin like growth factor 1 receptor
(IGF1R) and transforming growth factor beta receptor 1 (TGFBR1). Consistently, the
expression of IGF1R and TGFBR1 on circulating naive CD4+ T cells is reduced in patients with
MS. Thus, our study shows that exosomal let-7i regulates MS pathogenesis by blocking the
IGF1R/TGFBR1 pathway.
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Multiple sclerosis (MS) is an autoimmune disease of thecentral nervous system, in which inﬂammatory CD4+ Thelper 1 (Th1) and Th17 cells are pathogenic1,2. In
mice, Foxp3+ regulatory T (Treg) cells, originally deﬁned as CD4
+CD25+ T cells, can suppress the proliferation and function of
inﬂammatory T cells, thereby preventing the development of auto-
immune diseases3. Disruption of the balance between inﬂammatory
and regulatory T cells may thus underlie MS pathogenesis4. Previous
studies have found a reduced frequency of CD4+CD25+CD127
−Foxp3+ Treg cells in the peripheral blood of patients with MS5,6, as
well as functional impairment of CD4+CD25+Foxp3+ Treg cells in
patients with MS7,8. However, the underlying mechanisms of
alterations of Treg cells are unclear.
Micro RNAs (miRNA) are small non-coding RNAs that
function as post-transcriptional regulators of gene expression by
inhibiting translation of messenger RNAs (mRNA). Previous
studies have revealed critical functions of miRNAs in the
differentiation and function of helper T cells9,10. Alterations of
miRNAs in the circulation, inﬂammatory cell populations or
pathological samples of autoimmune diseases have also been
documented11,12. MiRNAs can be present in exosomes, which are
extracellular vesicles (EV) smaller than 150 nm in diameter.
Exosomes can affect the target cells via gene regulation, which is
mediated by transfer of miRNAs13–15. Exosomes are secreted
from various cell types into circulation, and are delivered to target
cells throughout the body. Gene regulation with exosomes, in
which extrinsic miRNAs exert direct effect on target genes in
recipient cells, is regarded as a form of intercellular commu-
nication, which differs from conventional communication by
cytokines and cell surface molecules15. Critical involvement of
exosomes has been demonstrated in various human disorders,
including cancer and neurodegenerative diseases16,17. Approxi-
mately 100 miRNAs have been shown to be dysregulated across
various tissues, including brain, blood and cerebrospinal ﬂuid
from patients with MS, but pathological effects have only been
reported for a small subset of these miRNAs12,18–20. Additionally,
exosomal miRNA function has not been studied in MS.
In this study, we isolate circulating exosomes from the blood of
patients with MS and evaluate potential pathogenic function of
these miRNA-containing exosomes in MS. We ﬁnd that exo-
somes derived from patients with MS (MS-exosome) can selec-
tively affect IFN-γ−IL-17A−Foxp3+CD4+ Treg cells in vitro.
Several miRNAs are more abundant in the MS-exosome than in
exosomes from healthy donors. Among those upregulated in
patients with MS, let-7i can suppress Treg cell induction by
inhibiting the expression of insulin like growth factor 1 receptor
(IGF1R) and transforming growth factor beta receptor 1
(TGFBR1). Our ﬁndings imply that altered miRNA expression in
MS-exosome may contribute to the pathogenesis by disrupting
the homeostasis of Treg cells.
Results
Treg cell frequency is decreased by MS-exosome. Exosomes are
secreted from various cell types, circulate in the body, and alter
the function of the recipient cells via delivery of the exosomal
miRNAs. To investigate the function of the circulating exosomes
carrying miRNAs in MS, we puriﬁed exosomes from the plasma
of healthy controls (HC) and patients with MS. The average size
of the vesicles puriﬁed from the plasma samples was 96.5 nm (n =
6, standard deviation: 17.9 nm). Most of the collected vesicles
were typical in size as exosomes, which are smaller than 150 nm
(Fig. 1a)15. Furthermore, they expressed conventional exosome
markers, CD9 and CD63, but lacked the expression of Cyto-
chrome c, a mitochondrial protein, which is not present in exo-
somes (Fig. 1b)21.
Given the critical contribution of cellular immunity in MS,
here, we focused on the possible action of exosomes against
T cells. We cultured peripheral blood CD3+ T cells from HC
under stimulation with anti-CD3 and anti-CD28 monoclonal
antibodies (mAb) in the presence of exosomes derived from
patients with MS (MS-exosome) or those from HC (HC-
exosome). Notably, after culture with MS-exosome, the frequency
of Foxp3+CD4+ T cells was signiﬁcantly reduced as compared to
that after culture with HC-exosome (p< 0.01, a one-way analysis
of variance (ANOVA)) (Fig. 1d). When the Foxp3+CD4+ T cells
were phenotypically subdivided, the frequency of IFN-γ−IL-17A
−Foxp3+CD4+ T cells, regarded as most suppressive Treg
cells8,22,23, reduced (p< 0.05, a one-way ANOVA), whereas the
frequency of Foxp3+CD4+ T cells secreting IFN-γ or IL-17A did
not differ signiﬁcantly between the two groups (Fig. 1c, d). It is
assumed that the majority of Foxp3+CD4+ T cells secreting the
inﬂammatory cytokines are activated inﬂammatory T cells in
which Foxp3 expression is transient, or those representing
dysfunctional Treg cells with impaired suppressive function
which are induced in the inﬂammatory cytokine milieu8,22–25. To
provide further conﬁrmation, we analysed the DNA methylation
status of the signal transducer and activator of transcription 5
(STAT5)-responsive region of the FOXP3 gene in these T cell
populations. CpG sites in the region are known to be
demethylated in functional Foxp3+ Treg cells23. The region
examined was moderately demethylated in IFN-γ−IL-17A−Foxp3
+CD4+ T cells, and clearly different from that of Foxp3+CD4+
T cells secreting IFN-γ or IL-17A, which was methylated to an
extent similar to that of Foxp3− non-Treg cells (Supplementary
Fig. 1a, b). Since IFN-γ−IL-17A−Foxp3+CD4+ T cells cannot be
acquired intact, we could not assess their regulatory function
directly. Instead, a pool of CD25+CD127−CD49d−CD4+ T cells
enriched in IFN-γ−IL-17A−Foxp3+CD4+ T cells were isolated
(Supplementary Fig. 1c). Subsequently, this population was
shown to possess a regulatory function against responder cells
(CD45RA+CD25−CD4+ T cells) in vitro (Supplementary Fig. 1d).
These data indicated that the IFN-γ−IL-17A− cells are the
functional Treg cell population among all Foxp3+CD4+ T cells,
whereas the remaining IFN-γ+ or IL-17A+ cells are not. This is
consistent with previous studies8,22–25. There was no signiﬁcant
difference in the frequency of potentially inﬂammatory CD4+
T cells such as those secreting IFN-γ, IL-17A or GM-CSF, after
culture with HC-exosome or MS-exosome (Fig. 1d; Supplemen-
tary Fig. 2). The frequency of IL-10+CD4+ T cells, which have
regulatory activity, was not altered by the presence of MS-
exosome (Supplementary Fig. 2).
Next, we cultured CD3+ T cells in the presence or absence of
HC-exosome labelled with PKH67 green ﬂuorescence lipid dye.
After 24 h, PKH67 ﬂuorescence was detected on the T cells
cultured with the labelled exosomes, but not on those cultured
without exosomes, supporting the occurrence of interaction
between exosomes and the T cells (Supplementary Fig. 3a, b).
Let-7i is increased in the exosomes from patients with MS. To
understand how MS-exosome affects Treg cells, we further ana-
lysed miRNA expression proﬁles in MS-exosome as compared to
those in HC-exosome. Results of microarray analysis, demon-
strated by cluster analysis and principal component (PC) analysis,
showed remarkable differences in miRNA proﬁles between MS-
exosome and HC-exosome (Fig. 2a, c), indicating the potential
value of the exosomal miRNA analysis for the diagnosis of MS.
Subsequently, we selected four miRNAs, let-7i, miR-19b, miR-25
and miR-92a for further analysis, the expression of which showed
most signiﬁcant differences between MS-exosome and HC-
exosome (Fig. 2b). The upregulation of these miRNAs was
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conﬁrmed by reverse transcription quantitative polymerase chain
reaction (RT-qPCR) (p = 0.0005, 0.001, 0.0004 and 0.001,
respectively, an unpaired t test) (Fig. 2d). The total amount of
RNAs in exosomes was not signiﬁcantly different between HC
and patients with MS (Fig. 2e). We expected that monitoring
expression levels of these miRNAs might prove to be useful for
distinguishing MS subtypes and evaluating the clinical activity.
However, no signiﬁcant differences were observed between
relapsing-remitting MS (RRMS) and secondary-progressive MS
(SPMS), or between MS in remission and relapse phases (Fig. 2d).
Sex and age had no signiﬁcant effects on the expression levels of
the four miRNAs (Supplementary Fig. 4a, b). These results
indicated that the exosomal miRNA proﬁle characteristic for MS
may be maintained after being shaped at a preclinical or very
early stage of the disease.
Treg cell frequency inversely correlates with exosomal let-7i.
We evaluated if the relationship might exist between the fre-
quency of the IFN-γ−IL-17A−Foxp3+CD4+ Treg cells after culture
(Fig. 1d) and the amount of miRNAs in the exosomes added to
the culture (Fig. 2d). It was ﬁrst noted that the amount of let-7i in
each exosome sample negatively correlated with the frequency of
IFN-γ−IL-17A−Foxp3+CD4+ Treg cells (p = 0.012, Pearson’s cor-
relation analysis) (Fig. 3a). This raised a possibility that let-7i may
participate in the bias for reduction of the Treg cell frequency. A
trend for negative correlation between miR-19b and Treg cells
was also observed, but it was not statistically signiﬁcant (p =
0.075, Pearson’s correlation analysis). No trends for correlation
were seen between the Treg cell frequency and either of the
remaining miRNAs (Fig. 3a). Because there was no difference in
the amount of total RNAs between HC and patients with MS
(Fig. 3b), we suspected that let-7i overexpressed in MS-exosome
might have a key function in the suppression of the IFN-γ−IL-
17A−Foxp3+CD4+ Treg cells in vitro. Additionally, we examined
the ratio of mature let-7i to primary let-7i in the T cells cultured
with HC-exosome or MS-exosome. MiRNA genes are transcribed
into primary miRNAs, which are then processed into mature
miRNAs during several steps in the nucleus and cytoplasm9.
Therefore, the mature let-7i/primary let-7i ratio in the cells could
be higher, if they actually uptake exogenous mature let-7i. Higher
mature let-7i/primary let-7i ratios were observed in T cells cul-
tured with MS-exosome as compared to those cultured with HC-
exosome (p = 0.022, an unpaired t test) (Fig. 3c). This observation
is consistent with the hypothesis that exosomal let-7i is actually
taken up by T cells and may exert some effects.
Treg cells but not Th1 or Th17 cells are affected by let-7i. To
evaluate the functionality of the miRNAs upregulated in MS-
exosome, CD3+ T cells from healthy donors were transfected with
let-7i, miR-19b, miR-25 or miR-92a, and cultured with anti-CD3
and anti-CD28 mAbs for 72 h. Subsequently, the frequencies of
inﬂammatory and regulatory T cell populations were evaluated by
ﬂow cytometer. Although the frequencies of IFN-γ+CD4+ T cells




































































































































Fig. 1 Exosomes from patients with MS can selectively decrease the frequency of Treg cells a Representative size distribution of puriﬁed exosomes. Using a
NanoSight LM10 nanoparticle analysis system, the size was analysed three times for each sample. Red error bars indicate the standard error of the mean. b
Western blot analysis for CD9, CD63 and Cytochrome c proteins. The PBMC and exosome samples were collected from HC. Each lane was loaded with 3
μg of protein for blotting. c Dot plot and histogram of ﬂow cytometry data. T cells were prepared from the peripheral blood of a healthy volunteer. They
were cultured with PBS as a control or with exosomes derived from HC (HC-exosome) or patients with MS (MS-exosome) under stimulation with anti-
CD3 and anti-CD28 mAbs for 48 h. IFN-γ−IL-17A−CD4+ T cells were deﬁned as shown in the left panel, and then the expression of Foxp3 was evaluated as
shown in the right panel. d The frequencies of inﬂammatory and regulatory T cells among CD4+ T cells after the culture described above. Among Foxp3
+CD4+ T cells, IFN-γ−IL-17A−Foxp3+CD4+ T cells are known to represent most effective Treg population8, 22, 23, whereas Foxp3+CD4+ T cells secreting
IFN-γ or IL-17A are supposed to be dysfunctional in the suppressive activity8, 22–25. Data are representative of two independent experiments. A one-way
ANOVA with Bonferroni’s comparison test was used for statistical analysis. Error bars represent the mean± s.d. *p< 0.05, **p< 0.01. s.d. standard
deviation, n.s. not signiﬁcant, ANOVA analysis of variance, Cyt c cytochrome c, PBMC peripheral blood mononuclear cell, EV extracellular vesicle, PBS
phosphate-buffered saline
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with the miRNAs, the frequency of IFN-γ−IL-17A−Foxp3+CD4+
Treg cells was signiﬁcantly decreased after transfection with let-7i
(p< 0.05, a one-way ANOVA) (Fig. 4a). In contrast, Foxp3+CD4
+ T cells secreting IFN-γ or IL-17A were not affected. Next, to
examine the involvement of let-7i in the effect of exosomes on
Treg cells, T cells were transfected with let-7i inhibitor and
cultured with exosomes as in Fig. 1d. No difference was noted in




































80 p = 0.0005
miR-19b miR-25 miR-92a
Total RNA amount
































































































































































Fig. 2 Exosomal miRNA proﬁle differentiates patients with MS from healthy controls a Heat map of miRNA expression proﬁle in the exosomes from HC and
patients with MS. RNA was extracted from exosomes, which were isolated from the plasma of four HC and four patients with MS. A 3D-Gene Human
miRNA Oligo chip (TORAY) was used for microarray analysis. MiRNAs with assigned identiﬁcation number lower than 500 and signal intensity higher than
100 were selected and clustered based on the expression patterns of the eight samples. b Volcano plot of miRNAs in the exosomes. The expression
difference of each miRNA between MS-exosome and HC-exosome is plotted on the X axis in log2 scale. p value of the difference by t test is plotted on the
Y axis. Blue dots represent miRNAs with signal intensity higher than 100. Green dots represent miRNAs with identiﬁcation number lower than 500 and
signal intensity higher than 100. Four miRNAs pointed by arrows (red dots) were identiﬁed as candidate miRNAs upregulated in patients with MS. They
were selected from green dots. c PC analysis for the MS and HC samples based on the miRNA expression proﬁles, using the same data as in b. d,e
Quantiﬁcation of the candidate miRNAs by RT-qPCR. The total amount of RNAs in the exosomes from the same amount of plasma was also examined.
Based on the clinical information, patients with MS were divided into those with RRMS or SPMS and into those in remission or relapse phase. An unpaired t
test was used for statistical analysis. Error bars represent the mean± s.d. s.d. standard deviation, n.s. not signiﬁcant, PC principal component, A.U. arbitrary
unit, RT-qPCR reverse transcription quantitative polymerase chain reaction, RRMS relapsing-remitting MS, SPMS secondary-progressive MS
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HC-exosome and MS-exosome groups after treatment with the
let-7i inhibitor (Fig. 4b). The rate of increase in the Treg cell
frequency after treatment with the let-7i inhibitor was greater in
the presence of MS-exosome than HC-exosome (p = 0.020, an
unpaired t test) (Fig. 4b), which was consistent with the result
that let-7i was more abundant in MS-exosome (Fig. 2d). Given
the inverse correlation between exosomal let-7i and Treg cell
frequency (Fig. 3a), the present result indicated that Treg cells are
the potential targets of let-7i, which is upregulated in MS-
exosome.
MS-exosome and let-7i inhibit Treg cell differentiation. To
further investigate the population that was inﬂuenced by MS-
exosome and let-7i and is responsible for the reduced frequency
of Treg cells after culture, four CD4+ T cell populations, including
naive, memory and Treg cells, were sorted based on the expres-
sion of CD25 and CD45RA. While naive and memory CD4+
T cells were sorted as CD45RA+CD25− and CD45RA−CD25−CD4+
T cells, resting Treg and activated Treg cells were deﬁned as
CD45RA+CD25+ and CD45RA−CD25high CD4+ T cells, respec-
tively (Fig. 5a). These Treg cells have been previously shown to
possess sufﬁcient regulatory function23. Each isolated population
was cultured with HC-exosome or MS-exosome under stimulation
with anti-CD3 and anti-CD28 mAbs for 72 h. MS-exosome
speciﬁcally inhibited the differentiation of IFN-γ−IL-17A−Foxp3+
Treg cells from naive CD4+ T cells as compared to HC-exosome
(p = 0.003, an unpaired t test) (Fig. 5b). In contrast, there was no
difference in the survival and proliferation of resting Treg and
activated Treg cells (Fig. 5b). The frequency of IFN-γ−IL-17A
−Foxp3+ Treg cells seemed to decrease among memory CD4+













































let-7i (mature / primary)































































































































Fig. 3 Expression of let-7i in exogenously added exosomes negatively correlates with Treg cell frequency. a Correlation between the frequency of IFN-γ−IL-
17A−Foxp3+CD4+ Treg cells and exosomal miRNAs. The same experiment as that described in the legend for Fig. 1 was repeated with a different set of
primary T cells and exosome samples. Along with the evaluation of the effect of exogenous exosome on Treg cells in the culture, we also quantiﬁed the
expression levels of miRNA in each added exosome sample. Here, we analysed the relationship between the miRNA levels and the frequency of IFN-γ−IL-
17A−Foxp3+CD4+ Treg cells. b The amount of total RNA. We also measured total RNA in the exosomes added to the cultures, showing no signiﬁcant
difference between HC and patients with MS. c Expression levels of mature let-7i and primary let-7i were evaluated by RT-qPCR in the T cells after culture
with PBS, HC-exosome or MS-exosome. Pearson’s correlation analysis was used in a, and an unpaired t test was used in b and c for statistical analysis.
Error bars represent the mean± s.d. s.d. standard deviation, n.s. not signiﬁcant, A.U. arbitrary unit, RT-qPCR reverse transcription quantitative polymerase
chain reaction, PBS phosphate-buffered saline
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signiﬁcant (Fig. 5b). Consistent with these ﬁndings, let-7i inhibited
the induction of IFN-γ−IL-17A−Foxp3+ Treg cells from naive CD4+
T cells (p = 0.006, an unpaired t test), and no signiﬁcant change in
Treg cells was noted among cultured memory CD4+ T cells, as well
as in the survival and proliferation of resting and activated Treg
cells (Fig. 5c). Next, mature and primary let-7i were quantiﬁed in
CD45RA+ naive CD4+ T cells in the peripheral blood of HC and
patients with MS to examine whether the amount is changed
in vivo. The ratio of mature let-7i to primary let-7i increased in
patients with MS (p = 0.012, an unpaired t test) (Fig. 5d), raising a
possibility that exogenous let-7i was acquired by naive CD4+
T cells. Furthermore, the mature let-7i/primary let-7i ratio posi-
tively correlated with the amount of mature let-7i in exosomes from
the blood (p = 0.042, Pearson’s correlation analysis) (Fig. 5d). These
results suggested that let-7i in circulating exosomes is actually taken
up by naive CD4+ T cells and then would inhibit their differ-
entiation into functional Treg cells in vivo.
Let-7i suppresses the expression of IGF1R and TGFBR1. To
understand the mechanism of let-7i-mediated inhibition of Treg
cell induction, we have attempted to identify target genes of let-7i.
Using an online database for target prediction, TargetScanHuman
(Release 6.2, 7.0 and 7.1)26, we were able to identify candidate
genes targeted by let-7i. Subsequently, we selected suppressor of
cytokine signalling 1 (SOCS1), IGF1R and TGFBR1 for further
analysis, as they are known to be associated with homeostasis of
Treg cells. A previous study suggested that restriction of
IFN-γ-STAT1 (signal transducer and activator of transcription 1)
signalling by SOCS1 is critical for stabilising Foxp3+ Treg cells27.
Accordingly, Socs1-deﬁcient mice developed a T cell-mediated
autoimmune inﬂammatory disease, as a result of defective Treg
functions characterised by an increase in phosphorylated STAT1
(pSTAT1)27,28. However, neither pSTAT1 nor STAT1 in CD4+
T cells was changed after transfection of let-7i in our culture
system (Supplementary Fig. 5), implying that SOCS1 does not
have a major function in the let-7i-mediated suppression of Treg
cells.
TGFβ has an important function during the differentiation of
Treg cells29, whereas IGF1 is known to expand Treg cell
populations in vitro, thereby inhibiting autoimmune diseases
and allergies30,31. Using blood samples from healthy volunteers, it
was conﬁrmed that exogenous IGF1 signiﬁcantly promoted
TGFβ-dependent differentiation of naive CD4+ T cells into
IFN-γ−IL-17A−Foxp3+CD4+ Treg cells (p = 0.031, an unpaired t
test) (Fig. 6a). Given that TGFβ- and IGF1-signalling pathways
promote induction of Treg cells, we evaluated the effect of let-7i































































































































































































































Fig. 4 Let-7i transfection decreases the frequency of Treg cells. a T cells were transfected with let-7i, miR-19b, miR-25 or miR-92a and then cultured under
stimulation with anti-CD3 and anti-CD28 mAbs for 72 h. The phenotype was determined by ﬂow cytometry based on cytokine expression (IFN-γ, IL-17A)
and transcription factor expression (Foxp3). Data are representative of two independent experiments. b T cells were transfected with let-7i inhibitor and
cultured in the presence of MS-exosome or HC-exosome under stimulation with anti-CD3 and anti-CD28 mAbs for 72 h. The frequencies of IFN-γ−IL-17A
−Foxp3+CD4+ Treg cells were analysed and the rates of increase by let-7i inhibitor were plotted. Data are representative of two independent experiments.
n= 6 in each group in a, n= 6 in each group with exosomes and n= 3 in the groups with PBS in b. A one-way ANOVA with Dunnett’s comparison test was
used in a, and an unpaired t test was used in b for statistical analysis. Error bars represent the mean± s.e.m. in a, and the mean± s.d. in b. *p< 0.05. s.e.m.
standard error of the mean, s.d. standard deviation, n.s. not signiﬁcant, ANOVA analysis of variance, PBS phosphate-buffered saline
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transfected with let-7i and cultured in the presence of anti-CD3
and anti-CD28 mAbs for 72 h. Notably, the expression of IGF1R
and TGFBR1 on the cultured CD4+ T cells was signiﬁcantly
decreased (p = 0.005 and 0.001, respectively, an unpaired t test)
(Fig. 6b). This is consistent with the premise that the 3’
untranslated regions (3’UTR) of these genes are targets of let-7
family32,33. To examine the involvement of IGF1R and TGFBR1
in the differentiation of Treg cells from naive T cells, naive CD4+
T cells were transfected with siRNAs targeting IGF1R and
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72 h. Knockdown of either or both of the receptors remarkably
inhibited the differentiation of Treg cells (p< 0.01, p< 0.001 and
p< 0.001, respectively, a one-way ANOVA) (Fig. 6c), indicating
that the IGF1R and the TGFBR1 pathways collaboratively
promote induction of Treg cells during their differentiation stage.
Knockdown of IGF1R and TGFBR1 decreases Treg cell fre-
quency. The in vitro analysis has not only conﬁrmed the function
of IGF1R and TGFBR1 in the differentiation of Treg cells, but
also raised the possibility that let-7i-mediated inhibition of TGFβ
signalling and IGF1 signalling might account for the reduction of
the Treg cell frequency in patients with MS, because let-7i was
also shown to inhibit differentiation of Treg cells (Fig. 5c). To
evaluate the relevance of this speculation, peripheral blood CD3+
T cells were transfected with various siRNAs and cultured for 72
h before ﬂow cytometry analysis. It was conﬁrmed that knock-
down of IGF1R with three different siRNAs resulted in a similar
reduction in the frequency of IFN-γ−IL-17A−Foxp3+CD4+ Treg
cells (p< 0.05 or p< 0.01, a one-way ANOVA), whereas IFN-γ+
or IL-17A+ CD4+ T cells were not reduced (Fig. 7a). Next, we
transfected T cells with TGFBR1-speciﬁc siRNAs in the presence
or absence of IGF1R-siRNA. The frequency of the Treg cells was
reduced after knocking-down TGFBR1, although it was not sta-
tistically signiﬁcant (Fig. 7b). We could neither reveal the additive
effects of TGFBR1 knockdown on IGF1R knockdown in reducing
Treg cells, nor could we show the signiﬁcant effects of TGFBR1-
speciﬁc siRNAs alone or with IGF1R-speciﬁc siRNAs on
inﬂammatory CD4+ T cells. In addition, TGFβ neutralisation
cancelled the reduced frequencies of Treg cells by knockdown of
TGFBR1 or IGF1R (Supplementary Fig. 6a and b), supporting a
fundamental function of TGFβ in the differentiation of Treg cells
as suggested in Fig. 6a.
TGFBR1 and IGF1R expression on T cells is decreased in MS.
To obtain supportive evidences for the alteration of let-7i-IGF1R/
TGFBR1 axis in patients with MS in vivo, we isolated peripheral
blood mononuclear cells (PBMC) from HC and patients with MS.
Consistently with previous reports5,6, the frequency of IFN-γ−IL-
17A−Foxp3+ Treg cells among memory CD4+ T cells was sig-
niﬁcantly decreased in patients with MS as compared to that in
HC (p = 0.047, an unpaired t test) (Fig. 8a). Strikingly, it was
found that the expression levels of TGFBR1 and IGF1R on
CD45RA+ naive CD4+ T cells were signiﬁcantly decreased in
patients with MS (p = 0.041 and 0.012, respectively, an unpaired t
test) (Fig. 8b, c). When the samples were grouped based on the
amount of let-7i in circulating exosomes (let-7i high and low; each
contains the same number of samples), the expression of TGFBR1
on naive CD4+ T cells was signiﬁcantly lower in the let-7i high
group than in the let-7i low group (p = 0.025, an unpaired t test)
(Fig. 8d). Signiﬁcant negative correlation between them was also
detected (p = 0.020, Pearson’s correlation analysis) (Fig. 8d).
Similarly, the persons with higher amounts of exosomal let-7i (let-
7i high) had decreased frequencies of IFN-γ−IL-17A−Foxp3+CD4
+ Treg cells in circulation (p = 0.043, an unpaired t test), although
the negative correlation was not signiﬁcant (Fig. 8d). This dis-
crepancy might indicate the involvement of factors other than
exosomal let-7i in the homeostasis of Treg cells, although it is
possible that validation with a larger sample size might blur the
discrepancy. Further analysis revealed a strong negative correla-
tion between the amount of let-7i in naive CD4+ T cells and IFN-
γ−IL-17A−Foxp3+CD4+ Treg cells (p = 0.0007, Pearson’s correla-
tion analysis) (Fig. 8e). In addition, a negative correlation was
observed between the expression of IGF1R and the amount of let-
7i in naive CD4+ T cells (p = 0.011, Pearson’s correlation analy-
sis). There was also a trend for inverse correlation between the
expression of TGFBR1 and the amount of let-7i in naive CD4+
T cells, though statistically insigniﬁcant (p = 0.081, Pearson’s
correlation analysis) (Fig. 8e). Moreover, a signiﬁcant correlation
was detected between the Treg cell frequency and the expression
of TGFBR1 or IGF1R on naive CD4+ T cells (p = 0.043 and 0.002,
respectively, Pearson’s correlation analysis) (Fig. 8f). These
ex vivo data are consistent with the in vitro studies, which showed
that let-7i-induced downregulation of IGF1R and TGFBR1
(Fig. 6b) may account for the inhibition of Treg cell induction
from naive CD4+ T cells (Fig. 6c). Furthermore, this level of
consistency between ex vivo and in vitro results would allow us to
hypothesise that let-7i upregulated in MS-exosome may act on
naive CD4+ T cells, and thereby cause the phenotypic changes in
those cells, resulting in the reduction of induced Treg cell fre-
quency in vivo. Relevance of this model should be tested in the
future by using various means, including clinical interventions
targeting exosomes and miRNAs.
Discussion
The implications of miRNAs in the pathogenesis of intractable
diseases, such as cancer, immune-mediated diseases and
neurodegenerative diseases, have lately received increasing
attention9–11,34,35. Notably, manipulating the expression of
certain miRNAs causes drastic biological changes in vivo, as
demonstrated in mouse disease models11. In the demyelinating
disorder, MS, it has been shown that lymphocyte populations
derived from either blood or inﬂammatory lesions accompany
altered expression of certain miRNAs12. Overabundance of
various miRNAs was also conﬁrmed in the serum or plasma
samples of patients with MS36–41. MiRNAs carried by exosomes
were shown to contribute to intercellular communications, in
which exosomes would transport and transduce the miRNAs into
the target cells, either close or distant from the cells of exosome
origin15. The exosome-derived miRNAs would actually alter the
gene expression and functions of the recipient cells13,14. For
example, exosomal miRNAs derived from breast cancer cells were
shown to damage the integrity of the blood–brain barrier and
promote metastasis to the brain, accounting for their preferential
metastasis to the brain21.
Fig. 5 Differentiation of Treg cells from naive CD4+ T cells is inhibited by MS-exosome and let-7i. a Gating strategy for isolation of naive CD4+ T cells
(CD45RA+CD25−), memory CD4+ T cells (CD45RA−CD25−), resting Treg cells (CD45RA+CD25+) and activated Treg cells (CD45RA−CD25high). b Each
population sorted as in a was cultured with HC-exosome or MS-exosome under stimulation with anti-CD3 and anti-CD28 mAbs for 72 h. TGFβ (1 ng/mL)
and IL-2 (50 U/mL) were added for the culture of naive CD4+ T cells. The frequency of IFN-γ−IL-17A−Foxp3+CD4+ T cells was analysed for cultured naive
and memory CD4+ T cells. The frequencies of dead and proliferated cells were analysed for cultured resting and activated Treg cells. c Each population
sorted as in a was transfected with let-7i or a negative control, and cultured in the same way as in b. Data are representative of two independent
experiments. d Naive CD4+ T cells were sorted from the peripheral blood of HC or patients with MS. Mature and primary let-7i were quantiﬁed by RT-
qPCR. Correlation between the amount of let-7i in exosomes in the blood and the ratio of mature to primary let-7i in naive CD4+ T cells was analysed. n= 3
in each group in c. An unpaired t test was used in b, c and d, and Pearson’s correlation analysis was used in d for statistical analysis. Error bars represent
the mean± s.d. in b and d, and the mean± s.e.m. in c. s.d. standard deviation, s.e.m. standard error of the mean, n.s. not signiﬁcant, A.U. arbitrary unit,
rTreg resting regulatory T cells, aTreg activated regulatory T cells, RT-qPCR reverse transcription quantitative polymerase chain reaction
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In the present study, we investigated the involvement of exo-
somal miRNA in MS pathogenesis. We ﬁrst showed that exo-
somes derived from patients with MS have potentials to reduce
the relative frequency of IFN-γ−IL-17A−Foxp3+CD4+ Treg cells
in culture by inhibiting their differentiation from naive CD4+
T cells (Figs. 1 and 5). Subsequent analysis of the expression of
exosomal miRNAs has demonstrated that the miRNA expression
proﬁles in MS-derived exosomes are characterised by over-
abundance of four miRNAs: let-7i, miR-19b, miR-25 and miR-92a
(Fig. 2). Notably, expression of let-7i in exosomes inversely cor-
related with the frequency of Treg cells in the culture of T cells
with exosomes (Fig. 3), and we found that this miRNA is capable
of reducing the frequency of the functional Treg cells (IFN-γ−IL-
17A−Foxp3+CD4+ Treg) via inhibition of their differentiation
from naive CD4+ T cells (Figs. 4 and 5).
It is widely recognised that a reduction of Foxp3+ Treg cell
frequency is an immunological hallmark of MS5,6. To identify the
target molecules of let-7i, we used an online database for target
prediction and found that insulin like growth factor 1 receptor
(IGF1R) and transforming growth factor beta receptor 1
(TGFBR1) are potential targets of let-7i. Actually, we have
revealed that the expression of IGF1R and TGFBR1 on T cells was
downregulated after let-7i transfection (Fig. 6b), whereas targeting
IGF1R and TGFBR1 by siRNA inhibited the differentiation of
Treg cells from naive T cells in vitro (Fig. 6c). Flow cytometry
analysis revealed that not only a reduction of Treg cell frequency,
but also reduced expression of IGF1R and TGFBR1 on naive
T cells, are characteristics of the peripheral blood of patients with
MS (Fig. 8a, c). Given that MS-derived exosomes and let-7i could
inhibit the in vitro induction of IFNγ−IL-17A−Foxp3+CD4+ Treg
cells by acting on naive CD4+ T cells, the observed changes in
naive T cells from the peripheral blood of patients with MS
suggested that exosomal let-7i may also target naive T cells
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Fig. 6 Let-7i transfection decreases expression of IGF1R and TGFBR1 on CD4+ T cells. a Induction of Treg cells in the presence of IGF1, TGFβ and IL-2. Naive
CD4+ T cells were cultured in the presence of various combinations of IGF1 (10 ng/mL), TGFβ (1 ng/mL) and IL-2 (50 U/mL) under stimulation with anti-
CD3 and anti-CD28 mAbs for 72 h. The frequency of IFN-γ−IL-17A−Foxp3+CD4+ Treg cells among CD4+ T cells was determined. b T cells were transfected
with let-7i and then cultured under stimulation with anti-CD3 and anti-CD28 mAbs for 72 h. Representative histograms of the expression levels of IGF1R
and TGFBR1 are shown. The expression levels of IGF1R and TGFBR1 were determined by measuring the frequency of each receptor-positive cells among
CD4+ T cells and the MFI of each receptor on CD4+ T cells. c Naive CD4+ T cells were transfected with siRNAs targeting TGFBR1 and IGF1R as indicated,
and then differentiated towards Treg cells with TGFβ (1 ng/mL) and IL-2 (50 U/mL) in addition to stimulation with anti-CD3 and anti-CD28 mAbs for 72 h.
The frequency of Treg cells was evaluated. Data are representative of two independent experiments. n= 3 a or 4 b and c in each group. An unpaired t test
was used in a and b, and a one-way ANOVA with Dunnett’s comparison test was used in c for statistical analysis. Error bars represent the mean± s.e.m.
**p< 0.01, ***p< 0.001. s.e.m. standard error of the mean, A.U. arbitrary unit, MFI mean ﬂuorescence intensity, ANOVA analysis of variance, IGF1R
insulin like growth factor 1 receptor, TGFBR1 transforming growth factor beta receptor 1
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peripheral blood was relatively low in persons with a higher
amount of exosomal let-7i compared to those with a lower
amount (Fig. 8d). However, we observed no signiﬁcant inverse
correlation between them, which might indicate the alteration of
other factors involved in the homeostasis of Treg cells. Further
studies with a larger sample size are needed to clarify the level of
involvement of such additional factors in the homeostasis. More
strikingly, the Treg cell frequency was signiﬁcantly correlated
with the molecules expressed by naive CD4+ T cells: let-7i,
TGFBR1 and IGF1R (Fig. 8e, f). The overall results, including the
upregulation of let-7i in the exosomes and downregulation of
TGFBR1 and IGF1R on naive T cells, raised the possibility that
alterations in the let-7i-IGF1R/TGFBR1 axis might underlie the
autoimmune pathogenesis of MS. There might be several
decreased miRNAs besides the four increased miRNAs validated
in Fig. 2, and possibly other differentially expressed nucleic acids,
proteins and lipids in circulating exosomes in patients with MS.
The relevance of these alterations to the phenotypic change in T
helper cells needs to be studied further.
According to previous studies, ~30 miRNAs are differentially
expressed in the sera or plasma samples of patients with MS as
compared with those of HC36–41. The function of these cell-free
circulating miRNAs has not been mentioned or has only been
speculated based on pathway analysis39–41. However, individual
miRNAs act against various cells equipped with divergent mRNA
proﬁles, which makes the situation complicated. Therefore, it is
hard to evaluate the relevance of speculated functions of each
miRNA, unless functional validation has been made. In the pre-
sent work, the functions of let-7i against human lymphocytes
have been experimentally validated and correlated with auto-
immune pathogenesis. Gandhi et al. previously described upre-
gulation of miR-2540 and miR-92a39 in the sera or plasma of
patients with MS, although it is unclear whether these changes
reﬂect the altered exosomal miRNA proﬁles. In contrast, upre-
gulation of let-7i and miR-19b in the circulation have not been
previously described regarding MS pathogenesis, indicating the
need for analysing exosomal miRNAs. Among the miRNAs
upregulated in the exosomes from patients with MS, let-7i is
distinguishable from the others, in that the other three can be
grouped in the same cluster or family. MiR-19b and miR-92a
belong to both the miR-17-92 and miR-106a-363 clusters42. Since
miR-25 and miR-92a belong to the same family of miRNAs42, we
speculated that miR-19b, miR-25 and miR-92a in exosomes may
have some function distinct from that of let-7i in MS pathogen-
esis, although we have not experimentally addressed this possi-
bility yet.
Although our results showed that homeostasis of Treg cells
could be regulated by exosomal let-7i, it is possible that other
immune cells may be an additional target of let-7i. In fact, a
previous study demonstrated that downregulation of let-7i in
lipopolysaccharide-stimulated dendritic cells (DC) promoted an































































































































































































































































































































































Fig. 7 SiRNA-mediated knockdown of IGF1R and TGFBR1 decreases Treg cell frequency. a T cells were transfected with three different siRNAs targeting
IGF1R, and then cultured under stimulation with anti-CD3 and anti-CD28 mAbs for 72 h. The expression of IGF1R was assessed by the MFI of the receptor
on CD4+ T cells. The frequencies of inﬂammatory and regulatory T cells among CD4+ T cells were evaluated. b T cells were transfected with two siRNAs
targeting TGFBR1, with or without one targeting IGF1R, and cultured in the same manner as in a. The expression of TGFBR1 and the frequencies of
inﬂammatory and regulatory T cells among CD4+ T cells were evaluated similarly. Data are representative of two independent experiments. n= 4 in each
group. A one-way ANOVA with Dunnett’s comparison test was used for statistical analysis. Error bars represent the mean± s.e.m. *p< 0.05, **p< 0.01,
***p< 0.001. s.e.m. standard error of the mean, A.U. arbitrary unit, MFI mean ﬂuorescence intensity, ANOVA analysis of variance, IGF1R insulin like growth
factor 1 receptor, TGFBR1 transforming growth factor beta receptor 1
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02406-2
10 NATURE COMMUNICATIONS |  (2018) 9:17 |DOI: 10.1038/s41467-017-02406-2 |www.nature.com/naturecommunications





































































































































































p = 0.043 p = 0.025
n.s.































g [%] [A.U.] [A.U.]
[A.U.]






























































































































































let-7i (naive CD4+T) let-7i (naive CD4+T)
Fig. 8 Treg cell frequency and expression of IGF1R and TGFBR1 by naive CD4+ T cells is decreased in MS. a The frequency of IFN-γ−IL-17A−Foxp3+ Treg
cells among memory CD4+ T cells in circulation. b Representative histogram showing the expression levels of IGF1R and TGFBR1 on CD45RA+ naive CD4+
T cells. c The expression levels of IGF1R and TGFBR1 were assessed by the MFI of the receptors on circulating CD4+ T cells. d The frequency of IFN-γ−IL-
17A−Foxp3+ Treg cells and the expression of TGFBR1 and IGF1R on naive CD4+ T cells were analysed between the groups with lower and higher amounts of
let-7i in exosomes in the blood. The groups were determined so as to be numerically equal. Correlation analysis was also performed. e Correlation analysis
between the amount of let-7i in naive CD4+ T cells and the frequency of IFN-γ−IL-17A−Foxp3+ Treg cells or the expression of TGFBR1 or IGF1R on naive
CD4+ T cells in patients with MS and HC. f Correlation analysis between the frequency of IFN-γ−IL-17A−Foxp3+ Treg cells and the expression of TGFBR1 or
IGF1R on naive CD4+ T cells in patients with MS and HC. An unpaired t test was used in a, c and d, and Pearson’s correlation analysis was used in d, e and f
for statistical analysis. Error bars represent the mean± s.d. s.d. standard deviation, n.s. not signiﬁcant, A.U. arbitrary unit, MFI mean ﬂuorescence intensity,
IGF1R insulin like growth factor 1 receptor, TGFBR1 transforming growth factor beta receptor 1
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signalling 1 (SOCS1)43, indicating that the decrease of Treg cell
frequency in patients with MS may be partly explained by the
effects of exosomal let-7i on DCs. The results of previous studies
addressing the immunoregulatory function of let-7 family also
raise the possibility that let-7i may target invariant NKT (iNKT)
cells44, IL-10-producing T cells45 or macrophages/microglia46.
Notably, iNKT cell frequency is reduced in the peripheral blood
of patients with MS47,48, whereas let-7 promotes differentiation of
IFN-γ-producing NKT1 cells but suppresses IL-4-producing
NKT2 cells by targeting a transcription factor PLZF44.
Regarding the involvement of extracellular vesicles (EV) in MS
pathogenesis, we may refer to a few reports indicating a patho-
genic function of microvesicles in MS. Microvesicles, the EVs
larger than exosomes, derived from platelets or endothelial cells
were increased in the circulation of patients with MS49. Such MS
patient-derived microvesicles reportedly disrupted endothelial
barrier in vitro49, and microvesicles from endothelial cells pro-
moted the proliferation of CD4+ and CD8+ T cells50. Another
study showed that microvesicles of myeloid origin were increased
in the cerebrospinal ﬂuid of patients with MS51. In mouse models
of MS (experimental autoimmune encephalomyelitis), such
microvesicles promoted inﬂammation in the central nervous
system51. Although the precise mechanisms underlying these
phenomena were not clear, a possible link with our work should
be addressed in the future studies.
Expression levels of some circulating miRNAs have been shown
to correlate with the disease course (RRMS or SPMS), severity or
duration of MS38–41, resulting in an assumption that they might
be useful as potential biomarkers for MS. In contrast, the increase
of the four exosomal miRNAs reported in this study was observed
irrespective of the disease course (RRMS or SPMS) or clinical
phases (relapse or remission) (Fig. 2), implying that exosomal
miRNA proﬁle may be persistently dysregulated in patients with
MS. Based on these results, we may speculate that circulating
miRNAs that correlate with disease status may be derived from
inﬂammatory lesions or cells involved in the inﬂammatory pro-
cess. On the contrary, persistently upregulated miRNAs might be
caused by environmental stimulus, which is also persistent during
the course of disease. It was reported that host-derived miRNAs in
the microvesicles would modify gut microbiota and affect severity
of experimentally induced colitis52. In turn, it was shown that
nematode-derived vesicles in the gastrointestinal tract modiﬁed
immunological defense of mice in vivo via transfer of nematode
miRNAs53. These studies indicate that exosomes can have an
important function in autoimmunity by mediating communica-
tion between host and gut microbiota. Several studies, including
ours, have revealed alterations of gut microbiota in patients with
MS and described its possible link with the immunopathogen-
esis54–57. Gut bacteria reduced in patients with MS may contain
those engaged in the production of short chain fatty acids, which
are responsible for the induction of Treg cells in the gut54. It is an
open question whether alterations in the gut microbiota in
patients with MS may somehow cause dysregulated exosomal
miRNAs and the defective Treg cells.
Methods
Human samples. We present demographics of the patients with MS and healthy
volunteers who agreed to provide peripheral blood for this study in Supplementary
Table 1. McDonald criteria58 was used to make diagnosis of MS. The Ethics
Committee of National Center of Neurology and Psychiatry approved the study
protocol. Written informed consent was obtained from all patients.
Isolation of exosomes. Exosomes were puriﬁed from the plasma according to a
previously described method, with some modiﬁcations59. Brieﬂy, plasma samples
were subjected to sequential centrifugation at 1200 × g for 15 min and at 2000 × g
for 20 min, and supernatant was collected after the ﬁnal centrifugation at 10 000 × g
for 45 min. The resultant supernatant was mixed with a one-ﬁfth volume of
polyethylene glycol buffer (30% PEG 6000, 50 mmol/L HEPES, 1 mol/L NaCl).
Exosomes were pelleted by centrifugation at 10 000 × g for 30 min and resuspended
in phosphate-buffered saline. The size distribution of collected exosomes was
determined using a NanoSight LM10 nanoparticle analysis system (NanoSight,
NanoSight Ltd, UK).
Transfer of PKH67-labelled exosomes. Puriﬁed exosomes derived from HC were
labelled using a PKH67 green ﬂuorescent labelling kit (MINI67-1KT, Sigma-
Aldrich, MO, USA). Exosomes were incubated with 2 μM of PKH67 and washed
using a 100-kDa ﬁlter (Amicon Ultra-0.5 mL, Millipore, Darmstadt, Germany) to
remove excess dye. A control solution was prepared by the same procedure without
exosomes. T cells were incubated with labelled exosomes or control solution for 24
h, followed by an examination using ﬂow cytometer (FACS Canto II, BD Bios-
ciences, NJ, USA) and ﬂuorescence microscopy (BZ-X700, KEYENCE, Osaka,
Japan).
Cell preparation and ﬂow cytometry. PBMCs were isolated by density gradient
centrifugation, using Ficoll–Paque PLUS (GE Healthcare Bioscience, ON, Canada).
They were stained for cell surface antigens, followed by intracellular staining using
Foxp3 / Transcription Factor Staining Buffer Set (00-5523-00, eBiosciences, CA,
USA) or BD Cytoﬁx Fixation Buffer/BD Phosﬂow Perm Buffer III (BD Biosciences,
CA, USA) according to the manufacturer’s instructions. The antibodies and isotype
controls used in this study were as follows: FITC-anti-Foxp3 (PCH101, diluted 10
times (10×)), FITC-rat IgG2aκ (eBR2a, (10×)) (eBiosciences, CA, USA), PE-anti-
STAT1 (1/Stat1, 10×), PE-anti-pSTAT1 (4a, 10×), PE-anti-IL-10 (JES3-19F1, 2×),
PE-mouse IgG1κ (MOPC-21, 10×), PerCP-Cy5.5-anti-CD49d (9F10, 5×), PE-Cy7-
anti-CD45RA (L48, 10×), APC-H7-anti-CD45RA (HI100, 10×) (BD Biosciences,
CA, USA), PE-anti-CD3 (UCHT1, 20×), PE-anti-IFN-γ (B27, 200×), PE-anti-
IGF1R (1H7/CD221, 10×), PE-anti-GM-CSF (BVD2-21C11, 5×), PerCP-Cy5.5-
anti-CD3 (UCHT1, 10×), PerCP-Cy5.5-anti-CD4 (RPA−T4, 20×), PerCP-Cy5.5-
anti-CD45RA (HI100, 20×), PE-Cy7-anti-CD25 (BC96, 20×), PE-Cy7-mouse
IgG1κ (MOPC-21, 10×), APC-anti-CD8 (SK1, 10×), APC-anti-IL-17A (BL168,
10×), APC-mouse IgG1κ (MOPC-21, 10×), APC-Cy7-anti-CD8 (RPA-T8, 10×),
BV421-anti-CD127 (A019D5, 10×), BV510-anti-CD8 (SK1, 10×), BV510-anti-
CD45RA (HI100, 10×) (all from BioLegend, CA, USA), APC-anti-rabbit IgG (711-
136-152, 3.3×) (Jackson Immuno Research Lab, PA, USA), puriﬁed anti-TGFBR1
(ab31013, 3.3×) (Abcam, Cambridge, UK). Proliferation and dead cells were ana-
lysed using CellTrace Violet Cell Proliferation Kit (C34557, Thermo Fisher Sci-
entiﬁc, MA, USA) and Zombie Aqua Fixable Viability Kit (423101, BioLegend, CA,
USA). Cells were analysed using FACS Canto II ﬂow cytometer (BD Biosciences,
CA, USA) and FlowJo software (Tree Star, OR, USA).
CD3+ T cells and naive CD4+ T cells were prepared using a pan T cell isolation
kit, Naive CD4+ T Cell isolation kit, and autoMACS Pro Separator (all from
Miltenyi Biotec, Germany) according to the manufacturer’s instructions.
Cell culture. To determine the functions of exosomes and miRNAs, T cells were
cultured with exosomes or after being transfected with miRNA mimics, inhibitors
and siRNAs as indicated. AIM V medium (Life Technologies, CA, USA) was used
for the culture. The exosomes were derived from the same amount of the plasma
and the T cells were prepared from HC or patients with MS. Culture plates were
coated with 2 μg/mL of anti-CD3 mAb (OKT3) and 4 μg/mL of anti-CD28 mAb
(Beckman Coulter, CA, USA) for 1 h at 37 °C before cells were added. In the
differentiation assay, naive CD4+ T cells were polarised towards Treg cells with 1
ng/mL of TGFβ and 50 U/mL of IL-2 (PeproTech, NJ, USA). An IGF1 recombinant
human protein (Thermo Fisher Scientiﬁc, MA, USA) was added in some experi-
ments as indicated. To neutralise TGFβ in the culture, 10 μg/mL of anti-TGFβ
antibody (1D11.16.8) was used. Resting and activated Treg cells, which were
transfected with a mimic of let-7i or a negative control, were cultured with ﬁve
times as many CD3+ T cells without transfection. To stain intracellular cytokines,
cultured cells were stimulated with 50 ng/mL of phorbol-myristate-acetate (Sigma-
Aldrich, MO, USA), 500 ng/mL of ionomycin (Sigma-Aldrich) and 2 μMmonensin
(Sigma-Aldrich) for 4 h just before staining.
For suppression assay, CD25−CD45RA−CD4+ T cells and CD25+CD127
−CD49d−CD4+ T cells were sorted after culture under stimulation with anti-CD3
and anti-CD28 mAbs for 48 h. CD45RA+CD25−CD4+ T cells were sorted as
responder cells from CD3+ T cells cultured with 1 U/mL of IL-2 for 48 h. CD3
−CD56− cells were sorted as APCs from PBMCs cultured without stimulation for
48 h. Responder cells (1 × 104) were stained with Violet Cell Proliferation Kit
(C34557, Thermo Fisher Scientiﬁc, MA, USA), and cultured with CD25−CD45RA
−CD4+ T cells or CD25+CD127−CD49d−CD4+ T cells (1 × 104) or without any
additional cells (control), in the presence of APCs (1 × 105) under stimulation with
anti-CD3 mAb for 120 h in RPMI medium (Thermo Fisher Scientiﬁc, MA, USA)
containing 10% of fetal calf serum (MP Biomedicals, CA, USA). Percentage of
suppression was determined based on division indices calculated with FlowJo
software (Tree Star).
Transfection of nucleic acid reagents. MiRNA mimics, inhibitors and siRNAs
were transfected using a P3 Primary Cell 4D-Nucleofector X Kit L and 4D-
Nucleofector system (LONZA, Basel, Switzerland) according to the manufacturer’s
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protocol. Five hours after transfection, cells were seeded onto a culture plate.
Materials used for transfection in this study were as follows: MISSION Human
miRNA Mimics of hsa-let-7i-5p, hsa-miR-19b-3p, hsa-miR-25-3p and hsa-miR-
92a-3p, and MISSION miRNA Negative Control 2 (all from Sigma-Aldrich, MO,
USA); mirVana microRNA inhibitor of hsa-let-7i-5p and a negative control
(Thermo Fisher Scientiﬁc, MA, USA); Silencer Select validated siRNAs of TGFBR1
and IGF1R, and Silencer Select Negative Control No. 1 siRNA (all from Thermo
Fisher Scientiﬁc, MA, USA).
RNA isolation and detection of miRNA and mRNA. Using Plasma/Serum Cir-
culating and Exosomal RNA Puriﬁcation Kit (51000, Norgen Biotek Corp., ON,
Canada), total RNA was extracted from the puriﬁed exosomes that were obtained
from the same amount of the plasma. 5 pg of celmiR-39 mimic (Applied Biosys-
tems, CA, USA) was added as an external control. RNA was subjected to com-
plementary DNA (cDNA) synthesis using a TaqMan MicroRNA Reverse
Transcription Kit (4366597, Applied Biosystems, CA, USA) and PCR was per-
formed using TaqMan Fast Advanced Master Mix and StepOnePlus realtime PCR
system (both from Thermo Fisher Scientiﬁc, MA, USA). The data of each miRNA
was analysed by the delta-delta Ct method using data of celmiR-39 and normalised
to the amount of applied RNA. The amount of total RNA was determined using
QuantiFluor RNA system (Promega, WI, USA). For detection of cellular RNA,
miRNeasy kit (217004, Qiagen, Venlo, Netherlands) was used in the extraction
step. MiRNA was then analysed with the same method as described above, and the
data was normalised to the expression of U6 snRNA. For analysis of mRNA or
primary miRNA, extracted RNA was subjected to cDNA synthesis using Prime-
Script RT Master Mix (TAKARA, Shiga, Japan) and PCR was performed using
TaqMan Fast Advanced Master Mix and StepOnePlus realtime PCR system. The
data was normalised to the expression of GAPDH (glyceraldehyde-3-phosphate
dehydrogenase). These primers were used: TaqMan MicroRNA Assays of hsa-let-
7i-5p, hsa-miR-19b-3p, hsa-miR-25-3p, hsa-miR-92a-3p and U6 snRNA; TaqMan
Pri-miRNA Assay of has-let-7i; and TaqMan Gene Expression Assay of GAPDH
(Applied Biosystems, CA, USA).
Methylation analysis of FOXP3 DNA. Genomic DNA was extracted as follows.
FACS-sorted cells were resuspended and lysed in 500 μL of lysis buffer containing
100 mM NaCl, 50 mM Tris HCl, 20 mM EDTA, 1% SDS and 0.1 mg/mL proteinase
K. The lysate was incubated in a thermoshaker at 50 °C for 14 h, and then subjected
to DNA extraction with 500 μL of mixture of phenol, chloroform and isoamyl
alcohol (25:24:1) (Nakalai tesque, Kyoto, Japan). After centrifugation at 20,000 × g
for 5 min, the aqueous (upper) portion was collected and subjected to reextraction
with 500 μL of chloroform (WAKO, Osaka, Japan). After centrifugation at
20,000 × g for 10 min, the aqueous (upper) portion was mixed with 500 μL of 2-
propanol (WAKO, Osaka, Japan), and centrifuged at 20,000 × g for 10 min. The
precipitated pellets were rinsed with 100 μL of 70% ethanol, and centrifuged at
20,000 × g for 5 min. The resultant DNA pellets were resolved in DNase-free water.
The methylation status of extracted DNA was examined (Alliance Biosystems,
Osaka, Japan). Brieﬂy, after bisulﬁte conversion using an EZ DNA Methylation-
Lightning kit (D5030, Zymo Research, CA, USA), bisulﬁte-treated DNA was
subjected to PCR with primers for ampliﬁcation of target regions of interest. The
percentage methylation was evaluated by pyrosequencing using a PyroGold reagent
kit and PyroMark Q96 ID (972804, Qiagen, Venlo, Netherlands). The analysed
CpG sites were located in the STAT5-responsive region of the FOXP3 gene, and the
same as the sites that were examined by the previous report23. The sequences of
used primers are as follows: PCR primers: 5′-GTTAAGTTTGTTGTAGGA-
TAGGGTAGT-3′ and 5′-AAATCTACATCTAAACCCTATTATCACA-3′;
sequence primer: 5′-GTGGTGTAGATGAAGT-3′.
Western blot. Proteins were extracted from exosomes and cells using RIPA Lysis
and Extraction Buffer (Thermo Fisher Scientiﬁc, MA, USA) containing Protease/
Phosphatase Inhibitor Cocktail (Cell Signaling Technology, MA, USA). The
extracted proteins were separated in XV PANTERA Gel (12.5%) (DRC, Osaka,
Japan) and blotted onto polyvinylidene ﬂuoride membranes (Merck Millipore,
Darmstadt, Germany). The membranes were blocked with 5% w/v Bovine Serum
Albumin (Sigma-Aldrich, MO, USA), followed by incubation overnight with pri-
mary antibodies as follows: anti-CD9 (SN4 C3-3A2, 500×, eBiosciences, CA, USA),
anti-CD63 (H5C6, 500×, BioLegend, CA, USA) and anti-Cytochrome c (D18C7,
1000×, Cell Signaling Technology, MA, USA). The membranes were then incu-
bated with secondary antibodies (HRP-linked anti-mouse IgG, A4416 or HRP-
linked anti-rabbit IgG, A6154, Sigma-Aldrich, MO, USA), and digital images were
obtained using ImageQuant LAS 500 (GE Healthcare, Bucks, UK) with an
Immobilon Western Chemiluminescent HRP substrate (Millipore, Darmstadt,
Germany).
Microarray analysis of miRNA. Total RNA was extracted from the puriﬁed
exosomes as described above. The RNA was subjected to a comprehensive gene
expression analysis using the 3D-Gene Human miRNA Oligo chip ver. 20, which
targets ~2500 miRNAs (TORAY, Tokyo, Japan). The 3D-Gene miRNA labelling kit
(TORAY, Tokyo, Japan) was used to label the RNA. Hybridisation signals were
examined using a 3D-Gene Scanner (TORAY, Tokyo, Japan).
Statistical analysis. Data were analysed with FlowJo software (Tree Star) and
Prism software (GraphPad Software, CA, USA). An unpaired two-tailed t test was
used to compare data from two groups, using Welch’s correction when variances
are unequal. A one-way ANOVA with Dunnett’s or Bonferroni’s comparison test
was used to compare data from more than two groups, as appropriate. Pearson’s
analysis was used to evaluate correlations. Differences were considered signiﬁcant
when the p value was< 0.05.
Data availability. Microarray data that support the ﬁndings of this study have
been deposited in the NCNI Gene Expression Omnibus database with the primary
accession code GSE86863.
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